Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: atomoxetine (Strattera) Clear all
Completed Phase 4 Interventional

Atomoxetine Pilot Study in Preschool Children With ADHD

NCT00517647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ATMX
Drug
Lead sponsor
University of Arizona
Other
Eligibility
3 Years to 5 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Evaluation of Continuous Symptom Treatment of ADHD

NCT00486122
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

NCT04905979
View directory record Official record
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
AD113, Atomoxetine
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Towson, Maryland • Cincinnati, Ohio • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dosing 1: Atomoxetine, AD313
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

NCT00190736
View directory record Official record
Conditions
ADHD
Interventions
Atomoxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 54 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
19
States / cities
Lafayette, California • Spring Valley, California • Farmington, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830
View directory record Official record
Conditions
Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Interventions
Accelerometer, placebo pill, Midodrine or atomoxetine pill
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

NCT00190957
View directory record Official record
Conditions
ADHD, Comorbid Alcohol Abuse
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
El Centro, California • Poway, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Withdrawn Not applicable Interventional

Progesterone and Atomoxetine for Cocaine Cessation

NCT01741376
View directory record Official record
Conditions
Cocaine Dependence, Nicotine Dependence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

NCT04565288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
14 Years to 20 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

NCT00485550
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Treatment of Executive Dysfunction in Parkinson's Disease

NCT00286949
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Atomoxetine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine in Veterans With Comorbid ADHD/PTSD

NCT02287038
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 MG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

Effects of Atomoxetine on Cognitive Function in Schizophrenia

NCT00420498
View directory record Official record
Conditions
Schizophrenia, Cognition, Smoking
Interventions
Atomoxetine (Strattera™)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Substance Abuse
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
12 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

NCT00485875
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 10, 2026, 10:04 PM EDT
Recruiting Phase 4 Interventional

Endotype DIrected Treatment for OSA in Down Syndrome

NCT07280468
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Down Syndrome
Interventions
ato-oxy, Oxygen
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

NCT00510276
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 30 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Los Angeles, California • Rolling Hills Est., California • Spring Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00880217
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Atomoxetine Treatment for ADHD and Marijuana Dependence

NCT00360269
View directory record Official record
Conditions
Marijuana Abuse, Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Motivational enhancement therapy, Placebo
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 10, 2026, 10:04 PM EDT
Completed No phase listed Observational

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

NCT04113551
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Atomoxetine in the Treatment of Binge Eating Disorder

NCT00327834
View directory record Official record
Conditions
Binge-eating Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 10, 2026, 10:04 PM EDT
Completed Phase 4 Interventional

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

NCT00506727
View directory record Official record
Conditions
ADHD
Interventions
Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 10, 2026, 10:04 PM EDT